MetaLabs said on the 27th that last year's revenue came to 81.4 billion won. That is about a 112% increase from the prior year's revenue (38.4 billion won). The operating loss was 7.1 billion won.
MetaLabs said, "Revenue rose sharply thanks to new businesses pursued last year and the consolidation of subsidiaries," and added, "The operating loss was due to bad-debt expenses, and results are expected to improve this year."
The company plans to make 2026 the first year of an earnings turnaround, based on expanded revenue. To that end, it will establish a foundation for generating operating profit by streamlining its business structure, strengthening expense control, and optimizing organizational operations.
Along with this, to strengthen its artificial intelligence (AI)-based Digital Healthcare capabilities, the company will bolster the customer relationship management (CRM) solutions business for nonreimbursable specialty hospitals such as hair loss and diet programs, conducted through subsidiary Meta S&C, and will advance it into an AI-based business model by linking it with medical data analytics and medical big data businesses.
A MetaLabs official said, "If last year was when we secured a foundation for top-line growth, 2026 will be the first year we establish a profitability-centered management structure," adding, "We will build a sustainable growth framework by strengthening the competitiveness of our core businesses."
METACARE, a company listed on the Korea Exchange's main board, is expanding its distribution network centered on supplying pharmaceuticals and medical devices to medical institutions. The company recorded 21.9 billion won in revenue and 2.5 billion won in operating profit in 2025.